Showing 1671-1680 of 10531 results for "".
Janssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeExpanding Social Media
https://practicaldermatology.com/topics/practice-management/expanding-social-media/18730/A lot of scrutiny happens in the social space. Social interaction can yield important benefits, but you need to disseminate valuable content and be sure to engage appropriately with your audience. ThisEkwa.com educational video offers guidelines for social media success.To Be Shorr: Your receptionist is director of first impressions
https://practicaldermatology.com/topics/practice-management/to-be-shorr-your-receptionist-is-director-of-first-impressions/18603/Th best physicians and surgeons can see their practice fall apart if they lack good staff. The receptionist is often the first contact a patient has with your practice. Think of this individual as your director of first impressions, says Mara Shorr, BS, CAC II-V.Summer AAD Highlights, Alopecia Areata Discovery
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-summer-aad-highlights-alopecia-areata-discovery/18846/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, new research that suggests emerging biologic therapies could help treat alopecia areata. Plus, updates on atopic dermatitis and eczema, hands-on education, and Kybella from the AAD Summer meeting. AndCosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.Dr. Joel Schlessinger discusses the importance of clinical research in your practice
https://practicaldermatology.com/topics/practice-management/dr-joel-schlessinger-discusses-the-importance-of-clinical-research-in-your-practice/19135/With hundreds of new products, procedures and technologies becoming available every day, it is important to keep up with the changing medical world. One way to do this is through clinical research at your practice. In this video, Dr. Joel Schlessinger discusses how he began his clinical research stuQuantel Derma LEDA Diode Laser System - Hair Removal at the Speed of Light
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/quantel-derma-leda-diode-laser-system-hair-removal-at-the-speed-of-light/19447/LEDA is the expandable platform system for permanent hair removal at the speed of light. LEDA applies photodynamic therapy (PDT) for the treatment of acne, Psoriasis, Vitiligo & atopic dermatitis, and for gentle skin rejuvenation. The diode laser system LEDA EPI, for hair removal, has a large spDermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improves